CenExel announces its role in Vertex Pharma’s studies in Journavx and celebrates US FDA approval

CenExel, a leading network of clinical research sites, congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the US FDA approval of Journavx (suzetrigine), the first-in-class, non-opioid oral pain signal inhibitor for adults with moderate-to-severe acute pain.

This landmark approval marks for the first time in 20 years, the US FDA has approved a new class of non-opioid pain medication, offering an alternative to addictive opioids for patients seeking pain relief.

Clinical trials for Journavx were conducted at four CenExel Centers of Excellence in Salt Lake City, UT; Tampa, FL; Anaheim, CA; and Atlanta, GA. These sites provided critical data that contributed to the US FDA’s decision, reinforcing CenExel’s commitment to advancing pain management research and delivering high-quality clinical trial execution.

The drug, suzetrigine, received US FDA approval will be available as a 50-milligram prescription tablet. The approval was announced by US FDA and it will be sold under the brand name Journavx by Vertex Pharmaceuticals.

“The approval of Journavx represents a monumental step forward in acute pain treatment,” said Ryan Brooks, CEO of CenExel. “For decades, the industry has been searching for a safe and effective alternative to opioids. Journavx has the potential to revolutionize how we treat pain while reducing the risk of addiction. At CenExel, we take immense pride in our role in supporting the research that has led to this breakthrough. This is exactly the kind of innovation that our Centers of Excellence strive to advance-one that has the power to change lives.”

Acute pain affects over 80 million Americans each year, with nearly half prescribed opioids. With Journavx’s approval, physicians now have a new, non-opioid treatment option that delivers effective relief without the risk of dependency, helping to reshape the acute pain treatment landscape.

As a premier provider of clinical research services, CenExel remains committed to supporting groundbreaking research that improves patient care.

CenExel is a leading, wholly owned, nationwide clinical research site network dedicated to supporting the life sciences industry in discovering and developing life-changing therapies, and provides unparalleled research support in the design and execution of complex clinical trials-leveraging scientific expertise, world-class Principal Investigators, advanced patient engagement strategies, premium data, and integrated operational excellence.

CenExel’s expertise and execution capabilities help pharmaceutical and biotech companies gain deeper insights into diseases, accelerating clinical development to deliver innovative treatments and improve global patient outcomes.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!